NCT02953743View on ClinicalTrials.gov

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

June 28, 2017

Study Completion Date

December 28, 2020

Conditions
Unresectable Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Lenvatinib

Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.

Trial Locations (3)

Unknown

Harbin Medical University Cancer Hospital, Harbin

Shanghai Cancer Hospital, Fudan University, Shanghai

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02953743 - Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter